Study finds orforglipron taken orally once daily leads to significant body weight loss

New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15–19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

Eli Lilly Rolls Out Its GLP-1 Strategy Worldwide

By partnering with telehealth firms and e-commerce platforms, the Mounjaro maker hopes to replicate its US success abroad as it moves into the EU, Asia and Middle East, Lilly’s international president told Reuters.

Medicare should cover GLP-1 obesity drugs

Despite the growing prevalence and impact of obesity in America, it took Medicare over 40 years to cover bariatric surgery, one of the first treatments for the disease. The decades-long delay in providing coverage for bariatric surgery in Medicare meant that an entire generation of Americans died from obesity-related diseases while waiting for access to […]

Lilly’s GLP-1 Pill Outperforms Older Novo Drug

Patients on Eli Lilly & Co.’s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk in the first head-to-head trial of the two medicines. Madison Muller reports on “Bloomberg Open Interest.”

Weight-loss drug giants face sternest test yet

The weight-loss drug boom has, in many ways, turned into a generational market story. For perspective, the U.S. obesity crisis touches 40% of adults, and weight-loss drug sales could top a whopping $100 billion by 2030 as GLP-1 use expands across diabetes into chronic weight management. At the center of it are Big Pharma plays […]

Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial – CNBC

Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial  CNBC Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine  Eli Lilly and Company Daily weight loss pill can help cut body weight by a fifth, trial shows  The Guardian Lilly’s […]

Eli Lilly posts full trial data for obesity pill (LLY:NYSE) – Seeking Alpha

Eli Lilly posts full trial data for obesity pill (LLY:NYSE)  Seeking Alpha Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial  CNBC Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine  Eli Lilly and Company Daily weight loss pill can […]